PURPOSE: Cardiac Troponins (cTnI, cTnT), NT-proBNP, and galectin-3 (GAL-3) mirror cardiomyocyte injury, stretch, and fibrosis. However, although these biomarkers has been thoroughly studied in marathon or ultramarathon, the effects occurring running shorter distances, as half-marathon, are less known and data are generally limited to immediately post-race evaluation. Moreover, significant variation of alpha-1 antitrypsin (AAT), an anti-protease factor with anti-inflammatory properties, has been recently observed in heart failure, but not investigated in paraphysiological settings. The aim of the study was to evaluate these biomarkers concentration and trends in trained runners before half-marathon run and during a 48-h recovery period. METHODS: In 18 half-marathon runners (15 males, 46 ± 6 years), cTnI, GAL-3 (Architect, Abbott), cTnT, NT-proBNP (Cobas e411, Roche), and AAT (Abcam, Cambridge, UK) were evaluated at rest, immediately post-run, and at 24 and 48-h recovery period. RESULTS: cTnT, NT-proBNP, and GAL-3 transiently increased after post-race, but normalized at 24 h (GAL-3 p < 0.01, cTnT < 0.001) or 48 h (NT-proBNP < 0.001), while cTnI and AAT did not significantly change. The frequency of values exceeding the diagnostic threshold, as evaluated at baseline and after the race, did not differ for cTnI ([Formula: see text] = 1.1, p = ns), and NT-proBNP ([Formula: see text] = 6, p = ns), but significantly increased for cTnT ([Formula: see text] = 23, p < 0.001) and GAL-3 ([Formula: see text] = 6.3, p < 0.05). None of the subjects showed AAT values exceeding the reference range at baseline and at any of the time points after the race. CONCLUSION: The transient cTnT, NT-proBNP, and GAL-3 increase may suggest a temporary stress on the myocyte. However, being the increase of all biomarkers moderate and reversible, it may represent a physiological response to acute exercise.
PURPOSE:Cardiac Troponins (cTnI, cTnT), NT-proBNP, and galectin-3 (GAL-3) mirror cardiomyocyte injury, stretch, and fibrosis. However, although these biomarkers has been thoroughly studied in marathon or ultramarathon, the effects occurring running shorter distances, as half-marathon, are less known and data are generally limited to immediately post-race evaluation. Moreover, significant variation of alpha-1 antitrypsin (AAT), an anti-protease factor with anti-inflammatory properties, has been recently observed in heart failure, but not investigated in paraphysiological settings. The aim of the study was to evaluate these biomarkers concentration and trends in trained runners before half-marathon run and during a 48-h recovery period. METHODS: In 18 half-marathon runners (15 males, 46 ± 6 years), cTnI, GAL-3 (Architect, Abbott), cTnT, NT-proBNP (Cobas e411, Roche), and AAT (Abcam, Cambridge, UK) were evaluated at rest, immediately post-run, and at 24 and 48-h recovery period. RESULTS:cTnT, NT-proBNP, and GAL-3 transiently increased after post-race, but normalized at 24 h (GAL-3 p < 0.01, cTnT < 0.001) or 48 h (NT-proBNP < 0.001), while cTnI and AAT did not significantly change. The frequency of values exceeding the diagnostic threshold, as evaluated at baseline and after the race, did not differ for cTnI ([Formula: see text] = 1.1, p = ns), and NT-proBNP ([Formula: see text] = 6, p = ns), but significantly increased for cTnT ([Formula: see text] = 23, p < 0.001) and GAL-3 ([Formula: see text] = 6.3, p < 0.05). None of the subjects showed AAT values exceeding the reference range at baseline and at any of the time points after the race. CONCLUSION: The transient cTnT, NT-proBNP, and GAL-3 increase may suggest a temporary stress on the myocyte. However, being the increase of all biomarkers moderate and reversible, it may represent a physiological response to acute exercise.
Authors: Thijs M H Eijsvogels; Maurits D Hoogerwerf; Martijn F H Maessen; Joost P H Seeger; Keith P George; Maria T E Hopman; Dick H J Thijssen Journal: J Sci Med Sport Date: 2014-01-02 Impact factor: 4.319
Authors: Zhaowei Kong; Jinlei Nie; Hua Lin; Keith George; Gang Zhao; Haifeng Zhang; Tomas K Tong; Qingde Shi Journal: Biomarkers Date: 2016-12-08 Impact factor: 2.658
Authors: R A de Boer; D J van Veldhuisen; R T Gansevoort; A C Muller Kobold; W H van Gilst; H L Hillege; S J L Bakker; P van der Harst Journal: J Intern Med Date: 2011-11-18 Impact factor: 8.989
Authors: Vincent L Aengevaeren; Aaron L Baggish; Eugene H Chung; Keith George; Øyunn Kleiven; Alma M A Mingels; Stein Ørn; Rob E Shave; Paul D Thompson; Thijs M H Eijsvogels Journal: Circulation Date: 2021-12-13 Impact factor: 29.690
Authors: Caroline Le Goff; Magalie Viallon; Jean-François Kaux; Pierre Andonian; Kevin Moulin; Laurence Seidel; Guido Giardini; Laurent Gergelé; Pierre Croisille; Etienne Cavalier; Gregoire P Millet Journal: Front Cardiovasc Med Date: 2022-03-07
Authors: Antonino Tuttolomondo; Carlo Maida; Alessandra Casuccio; Domenico Di Raimondo; Roberto Fonte; Valerio Vassallo; Maria Grazia Puleo; Tiziana Di Chiara; Alba Mogavero; Alessandro Del Cuore; Mario Daidone; Antonella Ortello; Antonio Pinto Journal: ESC Heart Fail Date: 2021-07-20